KR20220054359A - 혈관 질병을 치료하는 방법 - Google Patents

혈관 질병을 치료하는 방법 Download PDF

Info

Publication number
KR20220054359A
KR20220054359A KR1020227010117A KR20227010117A KR20220054359A KR 20220054359 A KR20220054359 A KR 20220054359A KR 1020227010117 A KR1020227010117 A KR 1020227010117A KR 20227010117 A KR20227010117 A KR 20227010117A KR 20220054359 A KR20220054359 A KR 20220054359A
Authority
KR
South Korea
Prior art keywords
mirna
hes
cells
hsa
mir
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227010117A
Other languages
English (en)
Korean (ko)
Inventor
나기사 사쿠라이
마리아 미로츠오우
누탄 프라세인
암리타 싱
로버트 란자
Original Assignee
아스텔라스 인스티튜트 포 리제너러티브 메디슨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스텔라스 인스티튜트 포 리제너러티브 메디슨 filed Critical 아스텔라스 인스티튜트 포 리제너러티브 메디슨
Publication of KR20220054359A publication Critical patent/KR20220054359A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Reproductive Health (AREA)
  • Materials For Medical Uses (AREA)
  • Gynecology & Obstetrics (AREA)
KR1020227010117A 2019-08-28 2020-08-27 혈관 질병을 치료하는 방법 Pending KR20220054359A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962892712P 2019-08-28 2019-08-28
US62/892,712 2019-08-28
PCT/US2020/048080 WO2021041592A1 (en) 2019-08-28 2020-08-27 Methods of treating vascular diseases

Publications (1)

Publication Number Publication Date
KR20220054359A true KR20220054359A (ko) 2022-05-02

Family

ID=72422305

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227010117A Pending KR20220054359A (ko) 2019-08-28 2020-08-27 혈관 질병을 치료하는 방법

Country Status (10)

Country Link
US (1) US20220280572A1 (cg-RX-API-DMAC7.html)
EP (1) EP4022042A1 (cg-RX-API-DMAC7.html)
JP (1) JP7876440B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220054359A (cg-RX-API-DMAC7.html)
CN (1) CN115003800A (cg-RX-API-DMAC7.html)
AU (1) AU2020337929B2 (cg-RX-API-DMAC7.html)
CA (1) CA3151637A1 (cg-RX-API-DMAC7.html)
IL (1) IL290892A (cg-RX-API-DMAC7.html)
TW (1) TW202122577A (cg-RX-API-DMAC7.html)
WO (1) WO2021041592A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102411018B1 (ko) 2015-08-18 2022-06-20 아스텔라스 인스티튜트 포 리제너러티브 메디슨 임상 제제
US20230027007A1 (en) * 2021-07-02 2023-01-26 Regeneron Pharmaceuticals, Inc. Treatment of Hypertension With Solute Carrier Family 9 Isoform A3 Regulatory Factor 2 (SLC9A3R2) Inhibitors
CN116832051B (zh) * 2023-07-08 2024-02-09 首都医科大学 抗氧化抗炎和促脂质代谢协同纳米给药系统

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070083A2 (en) * 2002-02-15 2003-08-28 Cornell Research Foundation, Inc. Endothelial precursor cells for enhancing and restoring vascular function
AU2007238660C1 (en) 2006-04-14 2013-11-07 Astellas Institute For Regenerative Medicine Hemangio-colony forming cells
CN101534747A (zh) * 2006-07-10 2009-09-16 哥伦比亚大学 从组织祖细胞和血管祖细胞从头形成和再生血管化组织
BRPI0912201A2 (pt) 2008-05-06 2019-09-24 Advanced Cell Tech Inc células formadoras de colônias de hemangios e células de hemangio não enxertantes
KR101920891B1 (ko) * 2010-08-27 2018-11-21 조슈아 엠 헤어 심장 치료를 위한 골수 유래 ｃｄ271 전구 세포
PL2785359T3 (pl) 2011-11-30 2018-12-31 Astellas Institute For Regenerative Medicine Mezenchymalne komórki zrębowe i związane z nimi zastosowania
US9428732B2 (en) * 2011-12-05 2016-08-30 Primorigen Biosciences, Inc. Compositions and methods for differentiating pluripotent stem cells into primitive blood cells and uses thereof
JP6746313B2 (ja) * 2012-08-01 2020-08-26 ユナイテッド セラピューティクス コーポレイション プロスタサイクリン処理された内皮前駆細胞による肺動脈性高血圧症の処置
CA2896053A1 (en) * 2012-12-21 2014-06-26 Ocata Therapeutics, Inc. Methods for production of platelets from pluripotent stem cells and compositions thereof
EP2970912B1 (en) * 2013-03-13 2019-03-06 Wisconsin Alumni Research Foundation Methods and materials for hematoendothelial differentiation of human pluripotent stem cells under defined conditions
CA2930304A1 (en) * 2013-11-13 2015-05-21 Cornell University Post-natal hematopoeitic endothelial cells and their isolation and use
US10626372B1 (en) * 2015-01-26 2020-04-21 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
KR102411018B1 (ko) 2015-08-18 2022-06-20 아스텔라스 인스티튜트 포 리제너러티브 메디슨 임상 제제
EP3383182B1 (en) * 2015-12-03 2023-06-07 The Brigham and Women's Hospital, Inc. Methods for generating functional hematopoietic stem cells
US11345895B2 (en) * 2016-11-18 2022-05-31 Wisconsin Alumni Research Foundation Induction of arterial-type of hemogenic endothelium (AHE) and enhancement of T cell production from PSCs through overexpression of ETS factors or modulating MAPK/ERK signalling pathways

Also Published As

Publication number Publication date
TW202122577A (zh) 2021-06-16
WO2021041592A9 (en) 2021-06-24
AU2020337929B2 (en) 2026-07-16
US20220280572A1 (en) 2022-09-08
JP2022547832A (ja) 2022-11-16
WO2021041592A1 (en) 2021-03-04
AU2020337929A1 (en) 2022-03-24
JP7876440B2 (ja) 2026-06-19
CA3151637A1 (en) 2021-03-04
EP4022042A1 (en) 2022-07-06
CN115003800A (zh) 2022-09-02
WO2021041592A8 (en) 2021-04-01
IL290892A (en) 2022-04-01

Similar Documents

Publication Publication Date Title
US12220432B2 (en) Cardiac stem cells for cardiac repair
US10787641B2 (en) Therapeutic use of CD31 expressing cells
Christoforou et al. Stem cells and their potential in cell-based cardiac therapies
Drela et al. Endothelial progenitor cells in diabetic foot syndrome
US20090092653A1 (en) Repair and regeneration of renal tissue using human umbilical cord tissue-derived cells
AU2018235964A1 (en) Methods and compositions for enhancing cardiomyocyte maturation and engraftment
CN111133099B (zh) 神经纤毛蛋白-1（nrp1）作为细胞表面标志物用于分离人心脏心室祖细胞的用途
KR20180136560A (ko) 폐질환 및 폐장애의 전염증성 매개체의 ｈＵＴＣ 조절
JP2016513962A (ja) 療法および予防のための細胞を単離する方法
JP2018135352A (ja) プロスタサイクリン処理された内皮前駆細胞による肺動脈性高血圧症の処置
KR20130106381A (ko) 심장 치료를 위한 골수 유래 ｃｄ271 전구 세포
US20220280572A1 (en) Methods of treating vascular diseases
KR20140054206A (ko) 제대 조직―유래 세포를 사용한 말초 혈관 질환의 치료
CN114164174A (zh) 含有适合用于缺血性疾病治疗的细胞的细胞群体的体外增殖方法
Bottai et al. Third trimester NG2-positive amniotic fluid cells are effective in improving repair in spinal cord injury
CN110462023B (zh) 作为有效成分包括组蛋白去乙酰化酶抑制剂和激活因子的干细胞活性促进用组合物
EP2776057B1 (en) A population of cells comprising placenta-derived cells which express cdx2 for use in treatment of damaged or degenerated heart tissue by inducing cardiac regeneration
Salvatori et al. Cells to repair the infarcted myocardium
Pesaresi Exogenous expression of chemokine receptors improves mouse mesenchymal stem cell migration towards the degenerating retina
Nguyen Cardiomyocyte Regeneration and the Potential Role of Neonatal Systemic Factors
Fazel Cardiac repair and not regeneration after myocardial infarction: the role and therapeutic utility of the c-kit
Gerbin Tissue Engineering Strategies to Improve Post-MI Engraftment of hESC-Derived Cardiomyocytes
Yagi et al. G-CSF augments small vessel and cell density in canine myocardial infarciton
Garcia Analysis of the regenerative potential of the induced pluripotent stem cells in a model of acute myocardial infarction in mice
Poole Cardiovascular therapeutics derived from the paracrine biology of adult human progenitor cells

Legal Events

Date Code Title Description
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000